MYND Life Sciences Inc. (MYNDF)
OTCMKTS
· Delayed Price · Currency is USD
0.0293
+0.0193 (193.00%)
At close: May 20, 2025
MYND Life Sciences Company Description
MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States.
It focuses on the analysis of psilocin and psilocybin extracts, and analogs. MYND Life Sciences Inc. is based in Port Coquitlam, Canada.
MYND Life Sciences Inc.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | John Campbell |
Contact Details
Address: Unit 150 Port Coquitlam, British Columbia V3C 2B2 Canada | |
| Website | myndsciences.com |
Stock Details
| Ticker Symbol | MYNDF |
| Exchange | OTCMKTS |
| Fiscal Year | November - October |
| Reporting Currency | CAD |
| ISIN Number | CA62857B1094 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Wilfred A. Jefferies | Co-Founder and Chief Science Officer |
| Lih-Ming Tam | Chief Financial Officer and Senior Controller |
| Dr. Chaahat S.B Singh | Senior Operations and Research Manager |
| Dr. Iryna Saranchova M.D., Ph.D. | Chief Clinical Officer |